General CAR-T cell and preparation method and application thereof

一种通用型、细胞的技术,应用在生物医药领域,能够解决耗时费力、评价周期长、经济性差等问题,达到避免细胞因子风暴、降低治疗成本、个体差异性小的效果

Pending Publication Date: 2019-05-21
BEIJING MENLO BIOLOGICAL TECH CO LTD
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although many remarkable progresses have been made in the construction of CAR, the adoptive immunotherapy system based on traditional CAR-T cells always has the following obvious defects: (1) It can only be autologous infusion
At present, although CAR-T can achieve good curative effect in the treatment of blood system diseases, it can only be infused autologously, that is, T cells are extracted from the patient's body, genetically modified, expanded, and then reinfused back to the patient.
Therefore, this form of treatment cannot be used as widely as drugs
Some patients cannot receive CAR-T reinfusion due to the inability to obtain a sufficient number of T cells, thus losing the possibility of treatment
(2) The preparation is cumbersome: each set of CAR-T system targeting a single tumor-associated antigen needs to be constructed separately, and its safety, targeting and effectiveness are tested through experiments, and the evaluation period for clinical application is long. Time-consuming and labor-intensive, less economical
(3) In the process of CAR-T cell adoptive immunotherapy, there is a lack of effective evaluation and monitoring methods for the targeting ability and biological metabolism of CAR-T cells in vivo, which often leads to overtreatment or ineffective treatment
[0008] However, these virus technologies have certain deficiencies. For example, after the lentivirus and retrovirus enter the cell, they will be randomly inserted into the genome, and the adenovirus will also have a certain probability of being inserted into the genome. , may damage the genes in the cells, resulting in cell abnormalities, and may even transform the cells into tumor cells, thereby causing tumors
Therefore, the use of these viral technologies to prepare CART for cellular immunotherapy has the risk of causing tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] The construction of embodiment 1 plasmid

[0071] 1. The plasmids constructed in this example include

[0072] LV-EF-1a-CD19CAR(4-1BB)-mCherry (positive control, see image 3 )

[0073] AAV6-TCR-CD19CAR (4-1BB) (experimental vector, see the structure diagram figure 1 , 4 )

[0074] AAV6-TCR-GFP (negative control, see figure 2 )

[0075] 2. Plasmid construction and virus packaging process

[0076] 2.1 LV-EF-1a-CD19CAT(4-1BB)-mCherry plasmid construction

[0077]The sequence is shown in SEQ ID NO:10.

[0078] Obtain LV-EF-1a-CD19CAR(4-1BB)-mCherry plasmid

[0079] First construct the plasmid map on ApE or Snapgene software.

[0080] The functional region of the plasmid: LTR-EF-1a-CD19CAT(4-1BB)-mCherry-LTR for gene synthesis.

[0081] The sequence was cloned into a lentiviral vector plasmid.

[0082] Plasmid transformation, smearing, picking clones, extracting plasmids (minor extraction), confirming correctness by sequencing, extracting plasmids again (major...

Embodiment 2

[0097] Embodiment 2 virus packaging process

[0098] 2.1 LV packaging

[0099] Prepare DMEM+10%FBS medium+antibiotics

[0100] Resuscitated 293T cells, subcultured, and judged that the cells were in good condition

[0101] The day before encapsulation, divide into 6 10cm culture dishes, each seed 2.5M cells, after 24 hours reach 70% confluence and then encapsulate.

[0102] Infection plasmids include: pSLQ5367, pCMV-dR8.91, pMD2-G, TransIT-Virus Reagent, Opti MEM.

[0103] The specific ratio is in accordance with the 10-cm dish in Table 1.

[0104] Table 1 Condition ratio of DNA transfection

[0105]

[0106] 2.2. AAV6 virus packaging

[0107] Taking T75flask as an example, the number of cells was 9M-10M when passaged in the afternoon of the previous day

[0108] Reagent name Reagent quantity

[0109] Vector plasmid 7.5ul (1.0ug / ul)

[0110] Packaging plasmid 7.5ul (1.0ug / ul)

[0111] Helper plasmid 7.5ul (1.0ug / ul)

[0112] OptiMEM 1.5ml

[0113] TanslT-VirusG...

Embodiment 3

[0116] Example 3 T cell sorting

[0117] 1. T cell sorting

[0118] 1. Obtain a blood sample (at least 50 mL) from a healthy donor. Eligible patients who have been tested for the following diseases (not limited to these tests). Including: hepatitis A, hepatitis B, hepatitis C, AIDS, syphilis antibodies, tuberculosis, genetic diseases, etc.

[0119] 2. Obtain peripheral blood mononuclear cells (PBMC)

[0120] 1) Mix Ficoll-PaqueTM PLUS (#07957) evenly and place in an empty tube;

[0121] 2) Dilute the blood sample (2X) with PBS+2% FBS;

[0122] 3) Place the blood sample in step 2) on the upper layer of the solution in step 1) to minimize the mixing of blood and Ficoll-PaqueTM PLUS, and centrifuge at 400g for 30 minutes at room temperature and then slow down naturally;

[0123] 4) Discard the upper layer of plasma after centrifugation in step 3), and take the interface layer between the plasma and Ficoll-PaqueTM PLUS solution, which is the peripheral blood mononuclear cells...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a physiological general CAR-T cell which enables expression of CAR to be controlled by an endogenous promoter and a preparation method and application thereof. A TCR constant region gene is knocked out by utilizing a CRISPR / Cas9 gene editing technique, and the CAR gene is inserted into a TCR constant region precisely by using an AAV-mediated homologous recombination technique. Therefore, the general CAR-T enabling the CAR expression controlled by the endogenous promoter and enabling the expression level of CAR be controlled within a normal physiological range can be obtained. The general CAR-T cell has the characteristics of being allogeneically infused, the expression of CAR is at the physiological level and uniform and consistent, no significant cytokine storm exists, and the cell is safer. The invention also relates to application of the CAR-T cell on anti-tumor aspect.

Description

technical field [0001] The present invention relates to the field of biomedicine, in particular to a universal CAR-T cell and its preparation method and application. Background technique [0002] CAR-T is an engineered T cell that uses an antibody fragment that can bind to a specific antigen to recognize antigens on the surface of tumor cells. In recent years, CD19 antigen-specific CAR-T cells have been used in clinical trials for the treatment of B-cell leukemia and lymphoma, showing extremely high response rates and sustained disease remission effects. Chimeric antigen receptors (CARs) endow T cells with the ability to recognize tumor antigens in an HLA-independent manner, which enables CAR-engineered T cells to recognize a wider range of targets than natural T cell surface receptors TCR. In recent years, CAR-T technology has shown remarkable efficacy in the treatment of acute leukemia and non-Hodgkin's lymphoma, and is considered to be one of the most promising tumor tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/10C12N15/90C12N15/864A61K35/17A61P35/00A61P37/06A61P37/02A61P37/08
CPCA61P35/00A61P37/02A61P37/06A61P37/08C12N5/10C12N15/864C12N15/90A61K39/464412A61K39/4611A61K2239/30A61K39/4632A61K39/4631
Inventor 芦志华朱滨董明洁
Owner BEIJING MENLO BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products